Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11739127-B2
Publication Date
2023-08-29
Expiration Date
Abstract
Provided herein are compositions related to vaccines, e.g., influenza vaccines, including, peptide based vaccines, nucleic acid based vaccines, recombinant virus based vaccines, antibody based vaccines, and virus based vaccines. Also provided herein are methods related to vaccines, e.g., influenza vaccines, including methods of identifying epitopes for the vaccines, producing, formulating, and administering the vaccines.
Core Innovation
The invention relates to influenza vaccine compositions and related embodiments centered on non-naturally occurring influenza epitope polypeptides and peptides. The compositions include engineered polypeptides constructed from defined influenza-virus epitope sequences, with sequence identity constraints to specified reference sequences (SEQ ID NOs). The claimed polypeptides are from the influenza virus and are not naturally occurring.
A core aspect of the invention is a multi-part polypeptide sequence that comprises a first sequence, second sequence, and third sequence, where each of these sequences corresponds to different SEQ ID NOs and each has at least 75% identity to its respective SEQ ID reference. The invention further includes additional sequence components and arrangement constraints, including directly linked configurations or inclusion of a specified linker sequence, such as RVKR (SEQ ID NO:110).
Beyond the polypeptide construct, the disclosure extends to related vaccine embodiments including polynucleotides encoding the polypeptides, vectors, recombinant viruses, and peptide cocktails. The disclosed vaccine embodiments are described as being administered to induce systemic or mucosal immunity, including cross-protection, and include an epitope-identification strategy using epitope invariance analysis with nucleic-acid libraries of pathogen mutants and screening for HLA binding/immunogenicity.
Claims Coverage
The partial document provides one explicitly identified independent claim, directed to a non-naturally occurring influenza polypeptide. Dependent claims further specify particular SEQ ID NOs, add additional sequence components, and constrain sequence arrangement, and the family extends to polynucleotides, vectors, recombinant viruses, compositions, and administration contexts.
Non-naturally occurring influenza polypeptide with three different SEQ ID identity-constrained sequences
A polypeptide comprising a sequence that comprises a first sequence, second sequence, and third sequence, wherein each of the first sequence, second sequence, and third sequence is a different SEQ ID NO and comprises at least 75% identity to a sequence selected from SEQ ID NOs: 40, 58, 61, 43, 51, 93, 22, 49, 82, and 34, and wherein the sequence is from the influenza virus and not naturally occuring.
Coverage centers on an engineered influenza polypeptide that combines three different SEQ ID NO-based sequence segments, each meeting a stated minimum identity threshold, and requires the resulting sequence to be from the influenza virus and not naturally occurring. The dependents further refine the specific SEQ ID NO usage, expand the construct with additional sequences, and constrain linkage using defined linker sequences.
Stated Advantages
Induce systemic or mucosal immunity, including cross-protection.
Documented Applications
Administering the vaccine embodiments to induce systemic or mucosal immunity, including cross-protection.
Use of polynucleotides, vectors, recombinant viruses, and peptide cocktails as influenza vaccine embodiments.
Interested in licensing this patent?